All In Biotech

Investigational drug · Phase 3

Zuberitamab

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Primary Membranous Nephropathy.

Phase 3

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

13

Any phase or sponsor naming "Zuberitamab"

First trial start

2024

Nov 13, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Zuberitamab", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Primary Membranous Nephropathy

Approved drugs for the same conditions: Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "Zuberitamab" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 10 on PubMed

Also in development for Primary Membranous Nephropathy

  • FelzartamabPhase 38 trials

    Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease

  • PovetaciceptALPN-303Phase 37 trials

    Vertex Pharmaceuticals · Immunoglobulin A Nephropathy, Myasthenia Gravis, Generalized, Primary Membranous Nephropathy

  • MIL62Phase 34 trials

    Beijing Mabworks Biotech Co., Ltd. · Systemic Lupus Erythematosus, Neuromyelitis Optica Spectrum Disorder, Primary Membranous Nephropathy

  • B007Phase 33 trials

    Shanghai Jiaolian Drug Research and Development Co., Ltd · Pemphigus, Primary Membranous Nephropathy, Generalized Myasthenia Gravis

  • CyclosporinPhase 32 trials

    Shanghai JMT-Bio Inc. · Primary Membranous Nephropathy

  • SHR-2173Phase 25 trials

    Guangdong Hengrui Pharmaceutical Co., Ltd · Generalized Myasthenia Gravis, Active Lupus Nephritis, Primary IgA Nephropathy

  • BudoprutugTNT119Phase 23 trials

    Climb Bio, Inc. · Primary Membranous Nephropathy, Systemic Lupus Erthematosus, Immune Thrombocytopenia (ITP)

  • FKC289Phase 22 trials

    Shenzhen Fosun Kairos Biotechnology Co., Ltd. · Primary Membranous Nephropathy, Primary Light Chain (AL) Amyloidosis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.